Description

ETOFORD 120 MG

Indications

ETOFORD 120 MG is primarily indicated for the treatment of moderate to severe pain in adults. It is particularly effective for patients who require around-the-clock management of pain that cannot be adequately controlled with non-opioid analgesics. This medication is often prescribed in various clinical settings, including post-operative pain management, chronic pain conditions, and cancer-related pain.

Mechanism of Action

ETOFORD contains the active ingredient Etoricoxib, which is a selective COX-2 inhibitor. It works by selectively inhibiting the cyclooxygenase-2 (COX-2) enzyme, which plays a crucial role in the inflammatory process. By blocking COX-2, Etofords reduces the production of prostaglandins, which are responsible for pain, inflammation, and fever. This mechanism allows for effective pain relief with a lower risk of gastrointestinal side effects compared to non-selective NSAIDs.

Pharmacological Properties

ETOFORD is characterized by its pharmacokinetic properties, which include rapid absorption and a bioavailability of approximately 100%. The peak plasma concentration is typically reached within 1 to 3 hours following oral administration. The drug has a half-life of approximately 22 hours, allowing for once-daily dosing. It is extensively metabolized in the liver, primarily through the cytochrome P450 enzyme system, and is excreted mainly in the urine as metabolites.

Contraindications

ETOFORD is contraindicated in patients with a known hypersensitivity to Etoricoxib or any of its components. It should not be used in individuals with a history of serious allergic reactions, such as anaphylaxis or angioedema, associated with other NSAIDs. Additionally, Etofords is contraindicated in patients with active peptic ulcer disease, severe renal impairment, or those who have undergone coronary artery bypass graft surgery. Caution should also be exercised in patients with a history of cardiovascular disease, as COX-2 inhibitors have been associated with an increased risk of cardiovascular events.

Side Effects

Common side effects associated with the use of ETOFORD include gastrointestinal disturbances such as nausea, diarrhea, and abdominal pain. Other potential side effects may include headache, dizziness, and peripheral edema. Serious adverse reactions, although rare, can occur and may include cardiovascular events, liver dysfunction, and renal impairment. Patients should be monitored for any unusual symptoms, and if severe side effects occur, discontinuation of the medication should be considered.

Dosage and Administration

The recommended dosage of ETOFORD for adults is 120 mg once daily. It can be taken with or without food, although taking it with food may help reduce gastrointestinal discomfort. The duration of treatment should be individualized based on the patient’s clinical condition and response to therapy. It is essential for patients to adhere to the prescribed dosage and not exceed the recommended daily limit to minimize the risk of adverse effects.

Interactions

ETOFORD may interact with other medications, which can affect its efficacy or increase the risk of adverse effects. Notably, concomitant use with other NSAIDs, anticoagulants, or antiplatelet agents can increase the risk of gastrointestinal bleeding. Additionally, drugs that affect liver enzymes, such as certain antifungals and antiepileptics, may alter the metabolism of Etofords. Therefore, it is crucial for patients to inform their healthcare providers about all medications they are currently taking, including over-the-counter products and supplements.

Precautions

Before starting treatment with ETOFORD, healthcare providers should conduct a thorough assessment of the patient’s medical history, including any history of cardiovascular disease, hypertension, liver or renal impairment, and gastrointestinal disorders. Regular monitoring of renal function and liver enzymes is recommended during prolonged therapy. Patients should also be advised to report any signs of cardiovascular events, such as chest pain or shortness of breath, and gastrointestinal symptoms, such as black stools or severe abdominal pain.

Clinical Studies

Clinical studies have demonstrated the efficacy of ETOFORD in managing pain associated with various conditions. In a randomized, double-blind study involving patients with osteoarthritis, ETOFORD was shown to significantly reduce pain and improve physical function compared to placebo. Another study focusing on post-operative pain management indicated that patients receiving ETOFORD experienced a notable reduction in pain scores and required fewer rescue analgesics compared to those receiving traditional NSAIDs. These findings support the use of ETOFORD as a valuable option for pain management in clinical practice.

Conclusion

ETOFORD 120 MG is an effective medication for the management of moderate to severe pain, offering a favorable safety profile compared to traditional non-selective NSAIDs. Its selective inhibition of the COX-2 enzyme provides significant pain relief while minimizing gastrointestinal side effects. However, careful consideration of contraindications, potential drug interactions, and patient-specific factors is essential to ensure safe and effective use. Ongoing monitoring and patient education are vital components of therapy to optimize outcomes and minimize risks.